Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease.
Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well.
QURE stock is now trading roughly 460% above its year-to-date low in early April.
Uniqure shares are rallying today primarily because “AMT-130,” the firm’s experimental therapy for Huntington’s disease, led to sustained reductions in mutant huntingtin protein in a clinical trial.
It’s the first time a gene therapy has demonstrated such a lasting biomarker response in Huntington’s disease, a fatal neurodegenerative condition with no approved cure.
Investors are pricing in the potential for QURE’s candidate therapy to emerge as the first-in-class treatment and unlock a multibillion-dollar opportunity for the Amsterdam-headquartered firm.
All in all, the top-line results elevate Uniqure’s status as a frontrunner in CNS gene therapy, which may help QURE stock price push further up from here through the remainder of 2025.
A royalty monetization agreement with Hercules Capital that brought Uniqure up to $175 million in non-dilutive funding also contributed to the surge in the biotech stock on Wednesday.
“This transaction provides us substantial capital to advance our pipeline without compromising ownership,” Matt Kapusta, the chief executive of Uniqure said in a press release today.
These developments made analysts at Stifel maintain their “Buy” rating and $raise their price objective from $30 to $65 on QURE shares today. While this is impressive, the average analyst price target is closer to $35.
Uniqure is currently trading for just below $50, indicating much of the related upside following the explosive rally this morning may already be priced into QURE stock at current levels.
Simply put, investors are recommended waiting for a pullback before initiating a new position in Uniqure stock.